FluoroPharma Medical, Inc.
FPMI · OTC
12/31/2016 | 12/31/2015 | 12/31/2014 | 12/31/2013 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.04 | -0.00 | 74.72 | 0.00 |
| FCF Yield | -23.56% | -29.78% | -31.47% | -20.19% |
| EV / EBITDA | -12.82 | -5.89 | -3.40 | -2.78 |
| Quality | ||||
| ROIC | 29.52% | 90.75% | 0.19% | 0.40% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.43 | 0.85 | 0.80 | 0.59 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | -100.00% | -100.00% |
| Free Cash Flow Growth | 67.16% | 27.04% | -10.21% | -0.47% |
| Safety | ||||
| Net Debt / EBITDA | -7.80 | -1.87 | -0.47 | 0.21 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -11,752.23 | -9,602.97 | 0.00 | 0.00 |